Numab

About:

Numab is a biotechnology company that offers antibody-based therapeutics for the treatment of severe diseases.

Twitter/X: numab_tx

Top Investors: BlackRock, Cormorant Asset Management, Mitsubishi UFJ Capital, Biotechnology Value Fund, RTW Investments

Description:

Numab is a biotechnology company that offers antibody-based therapeutics for the treatment of severe diseases such as chronic inflammation and cancer. It features a plug-and-play platform that substantially reduces the random nature of the discovery process to predictably yield ready-to-develop multispecific biotherapeutics.

Total Funding Amount:

122M CHF

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Wadenswil, Zurich, Switzerland

Founded Date:

2011-01-01

Contact Email:

info(AT)numab.com

Founders:

David Urech, Oliver Middendorp, Peter Lichtlen

Number of Employees:

51-100

Last Funding Date:

2022-12-05

IPO Status:

Private

Industries: